Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 4.63M.
Subavaliada
O PE mais recente da empresa é -3.14, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 123.80M ações, um aumento de 5.44% em relação ao trimestre anterior.
Mantido por Catherine Wood
O Super Investidor Catherine Wood possui 6.59M ações desta empresa.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.31.